澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ACDC Metals Ltd

0.055

+0.0047.84%

成交量：3,457.00

成交额：190.00

市值：412.12万

市盈率：-5.83

高：0.055

开：0.053

低：0.053

收：0.051

52周最高：0.160

52周最低：0.036

股本：7,493.08万

流通股本：4,028.75万

量比：0.10

换手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-0.009

每股收益(LYR):-0.009

净资产收益率：-6.71%

总资产收益率：-2.92%

市净率：0.41

市盈率(LYR):-5.83

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

先声药业(02096.HK)：SIM0609(CDH17抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书

招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级目标价63.5港元

阿斯利康第二款ADC药物在国内获批用于乳腺癌

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ADC.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ADC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","market":"AU","secType":"STK","nameCN":"ACDC Metals Ltd","latestPrice":0.055,"timestamp":1770613920000,"preClose":0.051,"halted":0,"volume":3457,"delay":0,"changeRate":0.07843137254901968,"nameEN":"ACDC Metals Ltd","floatShares":40287509,"shares":74930755,"eps":-0.00943,"marketStatus":"已收盘","change":0.004,"latestTime":"02-09 16:12:00 AEDT","open":0.053,"high":0.055,"low":0.053,"amount":190,"amplitude":0.039216,"askPrice":0.059,"askSize":50000,"bidPrice":0.055,"bidSize":215,"shortable":3,"etf":0,"ttmEps":-0.00943,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1770678000000},"marketStatusCode":5,"adr":0,"listingDate":1673787600000,"exchange":"ASX","adjPreClose":0.051,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":0.103419,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ADC.AU\",,,,,undefined,":{"symbol":"ADC.AU","floatShares":40287509,"roa":"-2.92%","roe":"-6.71%","lyrEps":-0.00943,"volumeRatio":0.103419,"shares":74930755,"dividePrice":0,"high":0.055,"amplitude":0.039216,"preClose":0.051,"low":0.053,"week52Low":0.036,"pbRate":"0.41","psRate":"11.96","week52High":0.16,"institutionHeld":0,"latestPrice":0.055,"committee":-0.991437,"eps":-0.00943,"divideRate":0,"volume":3457,"delay":0,"ttmEps":-0.00943,"open":0.053,"prevYearClose":0.065,"prevWeekClose":0.051,"prevMonthClose":0.049,"prevQuarterClose":0.065,"fiveDayClose":0.049,"twentyDayClose":0.06,"sixtyDayClose":0.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576048378","title":"Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576048378","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576048378?lang=zh_cn&edition=fundamental","pubTime":"2025-10-18 22:46","pubTimestamp":1760798760,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan (佳泰莱) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative  breast cancer  was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University . Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration  and was included in the priority review and approval process.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2799758/image_1.jpg?w=300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-presents-positive-results-of-phase-3-clinical-study-optitrop-breast02-for-sacituzumab-tirumotecan-in-advanced-hrher2--breast-cancer-at-2025-esmo-302588212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BC","BK4231","BK4203","BK7095","BK4190","HR","BK4225","ADC","ADC.AU"],"gpt_icon":0},{"id":"2565899846","title":"先声药业(02096.HK)：SIM0609(CDH17抗体偶联药物)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2565899846","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565899846?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 20:12","pubTimestamp":1757333548,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4231","ADC.AU","BK4080","02096","BK1583","BK1191","BK7095","ADC"],"gpt_icon":0},{"id":"2564325557","title":"招银国际：首次覆盖维立志博-B(09887.HK)予“买入”评级 目标价63.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564325557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564325557?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 14:14","pubTimestamp":1756966477,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169589451.USD","BK4023","ADC","PD","LU1169590202.USD","09887","BK4231","BK7095","BK4080","BK1161","ADC.AU"],"gpt_icon":0},{"id":"2561474908","title":"阿斯利康第二款ADC药物在国内获批用于乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474908","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561474908?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 20:38","pubTimestamp":1755866311,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LU2417539215.USD","BK4080","ADC.AU","BK4225","LU2456880835.USD","BK4585","LU1829250122.USD","LU2236285917.USD","LU0109394709.USD","LU0320765992.SGD","HR","BK4231","LU2462157665.USD","BK4568","LU0889565916.HKD","BK4007","AZN","BK4203","ADC","BK7095"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ADC.AU\",params:#limit:6,delay:true,,,undefined,":[]}}